The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ERCC1, KRAS mutation, redox status, and oxaliplatin sensitivity in colorectal cancer: “Radical” change in an old model.
Armando Orlandi
No relevant relationships to disclose
Mariantonietta Di Salvatore
No relevant relationships to disclose
Michele Basso
No relevant relationships to disclose
Cinzia BagalĂ 
No relevant relationships to disclose
Antonia Strippoli
No relevant relationships to disclose
Francesca Plastino
No relevant relationships to disclose
Enzo Dadduzio
No relevant relationships to disclose
Simona Di Lascio
No relevant relationships to disclose
Elisabetta Cursio
No relevant relationships to disclose
Alessia Amoruso
No relevant relationships to disclose
Mariagrazia Rodriquenz
No relevant relationships to disclose
Alessandra Cassano
No relevant relationships to disclose
Antonio Astone
No relevant relationships to disclose
Carlo Barone
No relevant relationships to disclose